ATF4 and hepatocellular carcinoma: Dihydroartemisinin (DHA) induces ferroptosis in hepatocellular carcinoma (HCC) by inhibiting ATF4, thus decreasing SLC7A11 expression and enhancing lipid peroxidation, also improving chemosensitivity to sorafenib, offering a novel therapeutic approach for HCC.